*2.3. Obesity-Link Adipocyte and Macrophage Crosstalk*

Adipocyte–macrophage crosstalk plays a central role in the induction and maintenance of obesity [95,96]. Macrophages constitute 40–60% of total cells in the adipose tissue depots of obese individuals, with an increase of ~5 fold, compared to lean [3,31]. Obese adipocyte-derived MCP-1, TNF-α and lipids, stimulate inflammatory monocyte infiltration and increase ATMs in adipose tissues [65,97]. Increased ATMs lead to higher levels of proinflammatory cytokines that cause further adipocyte dysregulation. ATM-derived TNF-α affects adipocytes by disrupting lipid and adipokine homeostasis, resulting in an increase of FFAs, among others. Adipocyte-induced FFAs further stimulate macrophages to express inflammatory cytokines. Hence, a disrupted macrophage–adipocyte crosstalk results in a harmful paracrine loop that exacerbates inflammation-mediated responses in the obese adipose tissue (Figure 2) [98–100]. Infiltrated ATMs in CLS are predominantly M1 phenotype, with just 10% in the outer rim of CLS accounting for M2 phenotype [39,43]. Initial studies suggested that adipocytes in CLS were highly necrotic in obese mice [101], while recent reports provide strong evidence that adipocytes undergo caspase-induced apoptosis [102,103]. Similar levels of adipocytes undergoing cell death were found in macrophage-depleted and control mice fed with HFD, suggesting that ATMs are not required for adipocyte cell death, rather the process is a response to elevated lipid dysregulation [104]. The ATMs in CLS function by taking up lipids, as well as removing the dead adipocytes through phagocytosis, and eventually form foam cells or become inactivated [105]. Further investigations on the understanding of the mechanistic nature of the macrophage–adipocytes crosstalk are much needed and guarantee to reveal vital knowledge, to help control obesity-induced inflammation.

#### **3. Flavones and Their Impact on Obesity-Induced Inflammation**

Obesity increases the incidence of heart disease by 30%, leads to diabetes, and is associated with cancer risk, as suggested by several meta-analyses [106]. Chronic inflammatory conditions represent one-third of the total \$1.1 trillion US health care expenditure, representing approximately 20% of the annual national GDP. The currently used medications for obesity, such as orlistat, (a pancreatic lipase inhibitor), and liraglutide (an incretin mimetic), have severe side effects that accrue to other undesirable symptoms [107]. Hence, identifying additional approaches that lack unwanted effects is necessary.

Flavonoids are a large class of plant phenolic secondary metabolites with anti-obesogenic, anti-inflammatory, and immune-modulating activities. Higher consumption of flavonoid-rich diet has been linked to reduced energy consumption, food intake, and weight loss [108]. Thus, flavonoids might offer an economically favorable approach, with minimal, if any, side effects for the prevention and treatment of obesity. Flavonoids are structurally characterized by two benzene rings and a heterocyclic pyrone ring. Based on the oxidation and saturation status of the heterocyclic ring, flavonoids are categorized into different sub-groups, such as flavones, flavonols, flavanones, flavanonols, flavanols, isoflavones, and anthocyanidins [6]. Flavonoids are potent antioxidant agents and the molecular mechanisms by which they mitigate free-radical-derived oxidative stress have been extensively reported elsewhere [8,109]. The health beneficial effects of flavonoids are mediated primarily through their ability to modulate multiple gene/protein signaling networks. However, the basic mechanisms of action are not completely understood. Several studies support the beneficial role of flavonoids in obesity. The flavonol quercetin, perhaps one of the most studied in the context of obesity, increases adiponectin and downregulates MCP-1, TNF-α, and IL-6 expressions in adipocyte macrophage co-cultures and HFD mice models, via the inhibition of the NF-κB, AP-1, and mitogen-activated protein kinase (MAPK) pathways [110]. Resveratrol, a flavonoid found in red wine, decreased insulin resistance, inflammation, and CCR2-driven macrophage infiltration in SAT and VAT in HFD-fed mice [111]. Several studies have reported that soy isoflavones promote lipid homeostasis and fatty acid metabolism, and inhibit macrophage–adipocyte crosstalk both in vitro and in vivo [112,113]. Investigations on flavonoids as potential agents for treating obesity-linked cancers and obesity-associated modulation of gut microbiota are gaining interest. Resveratrol and naringenin suppressed inflammation and breast tumor growth by inhibiting adipocyte hypertrophy and tumor associated macrophages (TAM) in obese mice [114,115]. Consumption of anthocyanin containing foods can protect against diet-induced obesity and systemic inflammation, by modifying the gut microbial population in mice [116]. Striking associations of the dietary flavonoid intake with decreased obesity were found in numerous meta-analyses [117,118]. These findings established flavonoids as prospective arsenals in fighting obesity and reinforced the significance of their use in our daily diets and in clinical trials. Flavones, a sub-class of flavonoids, are highly efficacious as anti-inflammatory and anti-obesogenic agents. Here, we focus this review on the role of flavones in the prevention and treatment of obesity and its related disorders.

#### *3.1. Flavone Sources and Structure*

Flavones are gaining immense interest due to their diverse bioactivity in plants and animals. They differ in structure from the other flavonoids in terms of the presence of a double-bond between C2 and C3 in the flavonoid core skeleton, a ketone at C4, and the absence of any modifications in the C3 position (Figure 3) [119]. The flavone core is subjected to substitutional conjugations, such as hydroxylations (addition of OH groups), glycosylations (bound to sugar moieties), or methoxylations (addition of methyl groups) at different positions, accounting for its expansive range of health beneficial activities [8]. Flavones are naturally found in plants as glucosides, conjugated either through hydroxyl groups (*O*-glycosides) or directly linked through the carbon (*C*-glycosides) groups. Functional activity, absorption, and bioavailability of these flavones can largely be dependent upon the structure, linkage, and the number of sugar moieties [120,121]. Most of the studies investigating the beneficial effects of flavones use them in their sugar-free form (aglycone). However, studies using whole foods with a high content of these phytochemical components in their naturally occurring form, remain scarce. We showed that aglycones are more easily absorbed than their glycosides, findings that are directly linked to their bioavailability and immunoregulatory functions [120]. Nevertheless, the poor solubility of aglycones imposes a great impediment for their clinical application in human health. We have overcome this gap in the field by developing foods from celery that increase the absorption and deliver bioactive concentrations of apigenin aglycone in vivo [120].

**Figure 3.** Structure of flavonoid core and different flavones.

The levels of flavonoids can significantly vary between plants and tissues. The common food sources of flavones include citrus fruits, vegetables, herbs, and grains. Albeit flavones represent only a small fraction of the total flavonoid intake, it is estimated to range between 0.7 to 9.0 mg/day [122]. Rich, natural flavone sources are parsley, celery, peppermint, and sage, which predominantly contain apigenin and luteolin in their *O*-glucoside forms [123]. In maize, maysin and apimaysin are common flavones modified in –*C* groups. Another group with a wide array of physiological effects is the methoxylated flavones, such as acacetin, diosmetin, and chrysoeriol, which are commonly found in the citrus family [124]. Despite the available and procuring knowledge on the bioactivity of pure flavones, further investigations on the effect of whole foods containing a high flavone content need to be adopted, with rigorous consideration on the estimation of consumption quantity. This is vital for overcoming hurdles in accurately interpreting the association between flavone intake and health outcomes at clinical levels.

#### *3.2. Role of Flavones in Obesity-Induced Inflammation*

Several studies have suggested promising effects of flavones on the prevention and treatment of obesity-induced inflammation, based on their ability to modulate adipocyte, as well as their immune cell function. Flavones inhibit different stages of adipogenesis by suppressing lipid accumulation in adipocytes, through the reduction of lipogenesis and lipolysis (Table 1).


**Table 1.** Flavones and their functional roles in obesity and its associated inflammation.

Apigenin and luteolin inhibit adipogenesis at 10–50 μM by attenuating the accumulation of intracellular triglycerides and the expression of adipogenic transcriptional factors, such as C/EBP and PPARγ, in differentiated 3T3-L1 and primary adipocytes, through the upregulation of 5- -adenosine monophosphate-activated protein kinase (AMPK) activity [125,133]. Apigenin and baicalein suppress proliferation and differentiation of preadipocytes, by inducing cell cycle arrest at G0/G1, and inhibiting MCE during the early stages of differentiation [126,137]. Lipid accumulation in mature human adipocytes and differentiated 3T3-L1 adipocytes was suppressed by apigenin, orientin (luteolin-8-*C*-glucoside), and baicalein. This suppression occurs through the reduction of lipolytic genes ATGL, HSL and monoacyl glyceride lipase (MGL), and lipogenic genes like fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC) and stearoyl-CoA desaturase (SCD), which reflect on the anti-lipolytic and anti-lipogenic role of flavones [127,138,140]. However, apigenin had no impact on adipogenesis or the expression of any of adipogenic genes, including SREBP-1c in mature human mesenchymal stem cell-derived adipocytes, while chrysin enhanced lipolysis, adipogenesis, and lipogenesis in differentiated 3T3-L1 cells [127,141]. Differences in these findings could be attributed to the etiology, the stage of differentiation of the cells used and the treatment dose, thus, highlighting the need for additional studies and the use of models that fully capture the complex balance of physiological whole-body metabolism. Reduction in transcriptional and translational levels of other adipogenic genes, such as FABP4 and GLUT4, were observed in the differentiated 3T3-L1 adipocytes treated with orientin and baicalein [138,140]. Chrysin enhances WAT thermogenesis by upregulating the expression of UCP-1 [141]. Although flavone glycosides apigetrin (apigenin 7-*O*-glucoside) and vitexin (apigenin 8-*C*-glucoside) suppressed adipocyte differentiation in 3T3-L1 cells, through the activation of the ERK/MAPK pathway, the flavone concentrations used were significantly high and unreachable in vivo in mice or human clinical trials, thereby possibly masking the key underlying mechanisms [143,144].

Anti-obesity responses of flavones were further corroborated using HFD obese mice models (Table 1). Baicalin (20 mg/kg/day), luteolin (5 mg/kg/day), apigenin (50 mg/kg/day), and vitexin (5 mg/kg/day) repress the expression of transcription factors associated with adipose differentiation, attenuate adiposity, and mitigate lipogenesis in WAT of HFD-fed C57BL/6J mice [128,134,139,145]. Apigenin (15–30 mg/kg) inhibit preadipocyte differentiation and visceral obesity in HFD-fed mice, by directly interacting with STAT3, hence inhibiting STAT3 transcriptional activity and reducing the expression of CD36 and PPARγ [129]. These results further support that flavones can exert their biological activities through direct binding to proteins. We previously demonstrated that apigenin binds with different affinities to 160 proteins, by screening a human peptide phage display library coupled with next generation sequencing (PD-Seq) [149]. Among these targets, cathepsin D (CTSD), was implicated as a pivot mediator in adipogenesis, lipid metabolism in mouse hepatic steatosis, mitochondrial dysfunction, cell death, and macrophage infiltration, in hypertrophic adipose tissues of genetically and HFD-induced obese mouse models [150,151]. Future mechanistic studies are vital to reveal the mechanisms of action of flavones in obesity-induced inflammation to facilitate its prevention and therapeutics.

Flavones inhibit obesity-induced inflammation by reducing macrophage numbers in adipose tissues, thereby diminishing a proinflammatory adipose environment (Table 1). Apigenin and chrysin reduce the levels of proinflammatory cytokines IL-12, TNF-α, IL-6, and MCP-1 in adipose tissue in obese C57BL/6J mice [132,142]. This effect seems to be due to the ability of apigenin to switch macrophage phenotype from M1 to M2 by binding to PPARγ, thereby suppressing the interaction between PPARγ and NF-κB. Luteolin also decreases the infiltration of ATMs in the EAT of HFD-fed mice, by reversing the polarization of obesity-associated M1 and MMe ATMs through the activation of the AMPKα1 pathway [135]. Interesting studies using adipocyte-RAW 264.7 macrophages co-cultures and cell-specific conditioned media revealed that luteolin reduces inflammation by suppressing macrophage-stimulated inflammatory cytokines, but has no effect on adipocytes-stimulated adipokines, suggesting that luteolin specifically targets macrophages [152]. An alternative explanation of these results could probably owe to the use of hypertrophic adipocytes, as it was previously reported that only preadipocytes and adipocyte

progenitors release chemokines such as MCP-1, to stimulate macrophage accumulation in adipose tissues, while their expression levels are low in mature adipocytes [153,154]. *Scutellaria baicalensis* roots rich in baicalin, wogonin, and luteolin alleviate HFD-induced insulin-resistance in obese mice, through modulation of inflammation, by promoting M2 phenotype skewing and reducing the TLR5 signaling pathway [136,146]. Flavones prevent non-alcoholic fatty liver disease (NAFLD) and steatosis. This effect seems to be due to the ability of flavones to increase liver fatty acid oxidation and reduce oxidative stress. Apigenin (50 mg/kg/day) reduces HFD/FFA-induced hepatic steatosis, lipid peroxidation, and lipid accumulation in the liver, by downregulating the lipogenic genes and inhibiting the overexpression of inflammatory markers and Kupffer macrophage infiltration [131]. These hepatic protective effects of apigenin were ascribed to its xanthine oxidase (a purine nucleotide degradation and ROS generator) inhibitor role, which hence inhibited the NLRP3 inflammasome assembly, ROS generation, and the release of inflammatory cytokines IL-1β and IL-18, illustrating a combined anti-oxidant and anti-inflammatory mechanism of action [131]. Oxidative stress was found to be mitigated by apigenin (30 mg/kg/day) and baicalin (50 mg/kg/day), by inhibiting the mitochondrial dysfunction through Nrf2 activation in adipocytes and macrophages in HFD/FFA-fed NAFLD mice [130,147]. Interestingly, induced activation of Nrf2 negatively regulated the PPARγ function in the NAFLD model, probably through direct interaction with Nrf2 [130]. Luteolin (5 mg/kg/day) decreases liver lipotoxicity by inducing FFAs flux to WAT and attenuates liver fibrosis by reducing cathepsin and extracellular matrix accumulation [136]. A quantitative proteomic study identified baicalin as an allosteric activator of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme of fatty acid β-oxidation, wherein it significantly improved hepatic steatosis and decreased diet-induced obesity, by directly binding with CPT1 to facilitate accelerated lipid influx into the mitochondria for β-oxidation and FFA degradation [148]. These findings underscore the efficacious nature of flavones in tackling obesity-induced inflammation, by actively affecting both the inflammatory macrophages and the adipocytes in the adipose depots, and also their crosstalk. Despite a large number of encouraging studies suggesting the health beneficial impacts of flavones, it warrants further investigation of the different upstream molecular mechanisms of their roles in modulating obesity-induced inflammation, using foods rich in flavonoids, at feasible treatment doses.

#### *3.3. Controlling Obesity-Associated Cancer Using Flavones*

Obesity was positively correlated with cancer morbidity and mortality in both men and women [155]. In addition, preclinical and epidemiological studies implicated obesity as a major risk factor for the development of cancer [156–158]. This is especially significant in the case of breast cancer, where the adipose tissue is a predominant component of the stroma in the mammary tissue [159]. Cancer cells spread to stromal compartments that possess abundant adipose tissue, while adipocytes along with ATMs serve as a tumor-favoring niche with endocrine resources to nurture and mold the tumor microenvironment, contributing to tumor progression and metastasis [160,161]. The insulin–insulin growth factor (IGF)-1 axis, sex hormones, and adipokines are key mediators between obesity and cancer, each of which are tightly linked to the endocrine and paracrine dysregulation of adipose tissue in obese individuals [162]. For instance, adipose-derived stem cells secrete chemokine adipsin and promote breast cancer growth [163,164]. Leptin released from adipose tissue is shown to induce vascular endothelial growth factor (VEGF) overexpression and enhanced cancer stem cell-like properties in breast cancer [165,166]. VAT-derived fibroblast growth factor (FGF)-2 was reported to stimulate cell transformation through FGF receptor-1 in melanoma and breast cancer [167].

Hypertrophic expansion of adipose tissues in obese individuals shares many common aspects with tumor growth. Both obesity and cancer progression are closely associated with energy intake and nutrient availability. Hypoxia, often linked to obesity, stimulates enhanced angiogenesis, creating a microenvironment that provides a tumor permissive niche for the transformed or infiltrating cells [168,169]. Certain fibrotic factors such as adipose-derived collagen-IV and endotrophin are the key mediators linking obesity and tumor growth [170–172]. While adipocyte-released mediators are the

predominant regulators of tumor progression, cancer cells can also induce metabolic differences and condition adipocytes in a pro-tumorigenic fashion, to form cancer-associated adipocytes (CAA) [173]. Paracrine signals from CAAs induce lipid degradation resulting in the release of FFAs, which is used as an energy source during metastasis by facilitating β-oxidation in cancer cells [174]. This reciprocal crosstalk between the cancer cells and adipocytes within the microenvironment is crucial for creating a tumor-permissive niche. Most importantly, both are characterized by chronic inflammation. Inflamed adipose tissues induce an aggravated expression of proinflammatory mediators, increased aromatase levels, and elevated estrogen receptor-α (ER-α)-dependent gene expression, which are also involved in tumor growth and metastasis [175,176]. Tumor cells also release MCP-1 to trigger macrophage infiltration, which are key contributions for tumor maintenance. While adipocytes recruit M1 phenotype macrophages, cancer cells skew macrophages towards an M2 phenotype [177]. Interestingly, adipocyte-cancer cell crosstalk was shown to influence chemotherapy efficacy and outcome in obese patients. The efficiency of tamoxifen to inhibit the proliferation of breast cancer cell line MCF-7 was significantly reduced in the presence of matured adipocytes derived from adipocyte stem cells of obese women. This effect was attributed to the increased presence of inflammatory adipokines, such as leptin, IL-6, and TNF-α, in the co-cultures of MCF-7 and adipocytes [178]. It is noteworthy that some of the key molecular players involved in obesity were also strikingly critical in cancer progression, such as NF-κB, CCL2/CCR2, JNK, and HIF/VEGF.

The anti-cancer efficacy of flavones relied on their ability to regulate key molecular pathways related to cancer cell proliferation and immune cell function, thereby halting tumor growth and metastasis [8]. Flavones inhibit cell growth and promote cell death in various cancer types. Importantly, we found that apigenin induces cell death of numerous cancer cell types but had no effect on the proliferation of non-cancer cells in leukemia [179]. We previously showed that apigenin induces cell cycle arrest by inducing DNA damage through the phosphorylation of ataxia-telangiectasia mutated kinase (ATM) and H2A histone family member X (H2AX) [180]. Luteolin induces apoptosis of colon cancer cells through its interaction with p53 and upregulation of Nrf2 [181]. In the human xenograft prostate cancer model, apigenin, through the inhibition of IGF/IGFR-1, reduced tumor growth [182]. Flavones can also suppress stem-like properties in aggressive cancers [183]. Baicalein inhibits the expression of stem cell markers CD44highCD24low and octamer-binding transcription factors (OCT)-3 and 4 in triple negative breast cancer cell lines, through the inhibition of interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) [184]. In addition, flavones are also potent immunoregulators. Apigenin and a celery-based apigenin-rich (CEBAR) food, a diet developed by our team that delivers in vivo effective doses of apigenin [120,185], reduce inflammation through the inhibition of NF-κB and decreased proinflammatory TNF-α in vivo [186,187]. Apigenin and luteolin suppress MCP-1 and IL-6 release, inhibiting TAM infiltration and migration of cancer cells [188–190]. These findings support the potent role of flavones in the prevention and treatment of obesity-induced cancers, and in enhancing the efficacy of chemotherapeutic drugs. However, further investigations on the effects of flavones on HFD-induced mammary tumorigenesis in preclinical PyMT mouse models are required, which can be significantly informative for clinical studies.

#### *3.4. Flavones as Emerging Mediators of Gut Microbiota and Its Link with Obesity-Induced Inflammation*

The gastrointestinal tract (GI) is inhabited by a broad repertoire of microorganisms, generically referred to as the gut microbiota. While the intestine provides a nutrient-rich, protected environment in which microbiota thrive to create a diverse and stable ecosystem, the microbiome provides nutrients to human host cells and prevent the entry of potential pathogens [191]. Microbes play an essential role in vitamin production, the modification of food components, energy homeostasis, intestinal mucosa formation, and the development of immunity. The gut microbiota interacts with the host cells through molecular communication, using small molecules and other metabolites [192]. Metagenomic analysis revealed that bacteria in the intestine belong to mainly three phyla, Bacteroidetes, Firmicutes, and Actinobacteria. Diet plays a drastic role in maintaining gut microbiota diversity [193]. An imbalance

in the composition, richness, and the metabolic activity of gut microbiota, known as dysbiosis, can give rise to dramatic changes in the symbiotic relationship between the bacteria consortium and the host, leading to a variety of chronic disease conditions, including obesity [194]. Obese individuals have an altered gut microbiota diversity with a reduction in barrier-protecting microbes, such as Lactobacillus and Bifidobacterium, and promotion of opportunistic pathogenic bacterial abundances like the Enterobacteriaceae, Desulfovibrionaceae, and Streptococcaceae families [195,196]. Compelling evidence demonstrating the role of the gut microbiota in obesity was provided by germ-free (GF) mice fed with HFD, showing a lesser weight-gain than non-GF mice, observations that were a result of enhanced fatty acid metabolism in GF mice [197]. Dysbiosis was found in both HFD and genetically induced obese mice, as evidenced by a 50% increase in the *Firmicutes* species and a 50% decrease in the *Bacteroidetes* species in obese conditions [198,199]. Additionally, transplantation of gut microbiome from genetically obese donor mice into GF mice increased adiposity, as compared to GF mice that received gut microbes from lean mice [200]. Similarly, dysbiosis and a significant reduction in bacterial diversity characterized by a higher *Firmicutes* to *Bacteroidetes* ratio were also observed in obese humans [201]. In HFD-induced obesity, enhanced growth of Enterobacteriaceae was correlated with an increase in intestinal endotoxin production, conditions that are known to contribute to an inflammatory intestinal microenvironment [202]. Intestinal bacteria inhibit fasting-induced adipocyte factor, which affects lipase activity and enhance triglyceride deposition in adipocytes. Furthermore, the obesity-altered gut microbiota is potent at harvesting energy from food by secreting enzymes that break down nutrients more efficaciously [200]. Strong links between diet, inflammation, and microbial dysbiosis were found. Increased fat intake causes a rise in Gram-negative bacteria, augmenting circulatory LPS levels and weakening the intestinal gut endothelium junctions that lead to enhanced intestinal permeability. Higher levels of IFN-γ and IL-1β increased gut epithelial permeability by suppressing the expression of tight junction proteins like occludin [203]. The innate immune system plays a critical role in regulating the crosstalk between the host and the microbiota during obesity-induced inflammation. An increase of macrophage infiltration into the intestinal lamina propia was observed in obese conditions, resulting from similar molecular mechanisms responsible for ATM infiltration [204,205]. LPS-induced TLR and NLR mediated the JNK and NF-κB pathways in intestinal epithelial cells and macrophages and stimulated the production of proinflammatory cytokines, which further impaired intestinal permeability. An abundance of *Bacteroidetes* and *Akkermansia muciniphila* increased in TLR4 and NLRP6 transgenic mice, thereby altering the microbiota profile and reducing inflammation [206,207]. HFD induced intestinal NF-κB and TNF-α expression and enhanced adiposity, which was resisted by the GF mice. Interestingly, intestinal changes induced by the HFD and microbiota-derived inflammatory changes seem to precede the onset of obesity [208]. Changes in the gut microbiota composition of genetically obese mice was associated with decreased MCP-1 levels [209]. HFD-induced alterations in gut microbiota spectrum hampered gut barrier function and enhanced macrophage infiltration and inflammation in mesenteric fat, suggesting a link between microbiota and inflammation [5]. These studies confirm that the microbiota is the main hub controlling the inflammatory responses in the intestine. There is growing evidence that establishes the role of microbiota in stimulating obesity-induced cancers. Fecal transfer from HFD-fed mice with aggressive intestinal tumor to healthy K-rasG12Dint mice led to a microbial community shift and enhanced tumor progression [210]. Transferring the microbiota from HFD-fed mice into female GF mice was associated with progressive hepatic cancer in the offspring [211]. Interestingly, *Akkermansia muciniphila* was identified to be associated with a favorable outcome in lung and renal cancer patients undergoing PD (programmed cell death protein)-1 immune checkpoint inhibitor chemotherapy, implicating the potential role of gut microbes in modulating host response to therapy [212].

The interplay between the gut microbiome and flavonoid metabolism is emerging as an important player in health [213,214]. The gut microbiota plays a key role in modulating the chemistry, bioavailability, and absorption of flavonoids. Intestinal microbial glycohydrolases, glucosidase, demethylation, dihydroxylation, and decarboxylation, modified flavonoids and the

resulting metabolites were more efficiently absorbed in the intestine. This was evident from their increased enterohepatic and plasma levels, and the elevated biological functions, as compared to their precursors [215]. Glycoside forms of flavonoids are often converted to their aglycones when metabolized by the gut microbiota [216]. Quercetin produced from the microbiota-mediated transformation of quercitrin (quercetin-3-*O*-rhamnoside) exhibited higher anti-inflammatory responses through the inhibition of the NF-κB pathway [217]. On the other hand, flavonoids can induce changes in gut microbiome composition, after the consumption of foods with a high content of polyphenols, predominantly via inhibition of pathogenic microbes and stimulation of commensal microbes [218,219]. Flavonoids might stimulate commensal bacteria *Lactobacillus* and *Bifidobacterium* in the gut microbiota, while hampering the colonization of the pathogenic strain *Clostridium*, thereby, reducing the gut microbiota dysbiosis [220]. Therefore, the reciprocal mutual effects involving the transformation of flavonoids by the gut microbiota and the modulation of microbiota by flavonoid and its metabolites can profoundly impact the flavonoid bioavailability, biological effects, and ultimately human health.

So far, studies on the effect of flavones on gut microbiota are lacking. However, studies reporting the beneficial role of other flavonoids as potent gut microbiota modifiers are emerging. For example, quercetin reduced the microbiota composition including the *Firmicutes*/*Bacteroidetes* ratio and the growth of species associated with diet-induced obesity like *Erysipelotrichaceae*, *Bacillus*, and *Eubacterium cylindroides*, while restoring the barrier integrity in obese NAFLD model [221,222]. In HFD/high sucrose-induced obesity models, polyphenol-rich cranberry extract diet and concord grape anthocyanins inhibited insulin resistance and inflammation by mediating an increase in *Akkermansia muciniphila* in the gut microbiota [116,223]. Anthocyanins from plum and peach juices decreased fecal short-chain fatty acids (SCFA), a subset of key gut microbiota metabolites, including acetate, propionate, and butyrate, and modified the bacterial composition of the microbiota, by increasing the population of *Faecalibacterium*, *Lactobacillus*, and *Bacteroidetes*[224,225]. Several flavonoids are shown to enrich beneficial bacterial abundance while reducing potential detrimental microbes in the human gut. Quercetin and resveratrol decreased the Enterobacteriaceae family and reduced the *Firmicutes*/*Bacteroidetes* ratio in the human gut, as shown through the 16S rRNA sequencing of fecal samples [226,227]. Diet supplementation with soy bars significantly enhances the abundance of beneficial *Bifidobacterium* bacteria in postmenopausal women, which results in increased lipid catabolism [228]. The ability of other flavonoids to regulate dysbiosis establishes a promising platform, urging the investigation of the potential of flavones in the regulation of the gut microbiota.

Studies related to the effect of flavone apigenin on the gut microbiota are gaining interest. Apigenin suppressed colonic inflammation by reducing IL-1β and IL-6 and immune cell infiltration [9]. Using NLRP6-/- mice and 16S rRNA gene sequencing of fecal samples, anti-inflammatory and anti-proliferative activity of apigenin was correlated to the apigenin-induced changes in the gut microbial composition, which was dependent on NLRP6 inflammasome. Notably, cohousing with apigenin-treated mice protected other mice against colitis, suggesting that the protective effects of apigenin were transmitted [229]. Apigenin inhibited *Enterococcus caccae* by upregulating genes pertaining to protein synthesis, DNA damage responses, and SCFA production, as identified by the 16S rRNA gene sequencing of apigenin-treated human fecal homogenates [230]. These findings suggest the potential role of apigenin as an active ingredient in modulating gut microbiota and hence mitigating obesity. To the best of our knowledge, studies pertaining to the effects of flavone intake on gut dysbiosis in humans remain to be reported. More studies considering the efficacy of various flavones in obese mouse models, as well as amongst humans within and between different regions, ethnicity, exercise regimes, and diets in regulating the intricate association between the gut microbiome and the immune system are necessary. Hence, an exhaustive understanding of the role of foods with a high content of flavones in the crosstalk between diet, gut microbiome, and immune system can provide a breakthrough in reducing obesity-induced inflammation.

### **4. Conclusions**

Obesity and associated comorbidities have reached pandemic levels and require the identification of additional therapeutic and preventive approaches that lack adverse side effects and are cost-effective. Chronic inflammation has a crucial role in the initiation and maintenance of obesity, promoting metabolic dysregulation, microbiome dysbiosis, and increasing cancer incidence. A vicious crosstalk between adipocytes and the infiltrated immune cells led to a dramatic remodeling of the gene, protein, and lipid metabolic networks. Flavones, active plant metabolites or nutraceuticals, provide potential opportunities targeting numerous pathways that are central to obesity. The established evidence demonstrates that flavones ameliorate macrophage-mediated inflammation and reduce cancer progression and obesity. These recent findings underscore the efficacious nature of flavones in tackling obesity as a "sword of two edges", targeting macrophages and adipocytes, thus, reestablishing homeostasis. Studies on the health beneficial impacts of flavones through the modulation of adipogenic and immunogenic regulators warrant further investigation and future exciting discoveries.

**Author Contributions:** A.I.D. conceptualized the content; M.S. and A.I.D. contributed to the design and the writing of the manuscript. A.I.D. supervised the manuscript. A.I.D. acquired funding. M.S. is a predoctoral T32 fellow. All authors have read and agreed to the published version of the manuscript.

**Funding:** Work in Dr. A.I. Doseff's lab was supported by grant USDA-AFRI-2018-03994, NSF-IOS-1733633, USDA-AFRI-2020-67017-30838, and MSU general funds. Meenakshi Sudhakaran was supported by a graduate research fellowship support from the Plant Biotechnology for Health and Sustainability Training Program Project NIH T32-GM110523.

**Acknowledgments:** We apologize to the colleagues who made important contributions, but which were omitted due to space limitations.

**Conflicts of Interest:** The authors declare no conflict of interest.
